Drugs / EuCorVac-19
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04783311 | Feb → Oct 2021 | COVID-19 | EuBiologics Co.,Ltd | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05572879 | Oct 2022 → Jun 2023 | COVID-19 | EuBiologics Co.,Ltd | Completed | No outcome recorded |
| Phase 3 | NCT05603052 | Jul 2022 → Jan 2024 | COVID-19 | EuBiologics Co.,Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EuCorVac-19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05572879 ↗ |
| Known as | ECV19 | “EuCorVac-19 (ECV19) is a recombinant protein nanoparticle vaccine that displays the SARS-CoV-2 receptor-binding domain (RBD) on immunogenic nanoliposomes.” PMID 36447243 ↗ Nov 20221“EuCorVac-19 (ECV-19) is a recombinant receptor binding domain (RBD) COVID-19 vaccine” PMID 39318203 ↗ Sep 2024 |
| Modality | Vaccine | “EuCorVac-19 (ECV19) is a recombinant protein nanoparticle vaccine that displays the SARS-CoV-2 receptor-binding domain (RBD) on immunogenic nanoliposomes.” PMID 36447243 ↗ Nov 2022 |
| Route | Intramuscular | “vaccinated intramuscularly on day 0 and day 21” PMID 36447243 ↗ Nov 2022 |